P30-EPS

**P30-EPS** is an investigational multipeptide therapeutic cancer vaccine developed at Duke University for newly diagnosed, MGMT-unmethylated glioblastoma. It combines HLA-A*02:01-restricted peptide antigens derived from ephrin type-A receptor 2, cytomegalovirus pp65, and survivin with the tetanus-toxoid-derived universal CD4+ helper epitope P30. The vaccine is intended to enhance coordinated CD4+ helper and CD8+ cytotoxic T-cell responses against glioblastoma-associated antigens and has been evaluated by intramuscular administration with the poly-ICLC adjuvant Hiltonol in the phase 1b ETAPA I trial. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05283109))

Other names

P30-EPSP-30-EPSP 30-EPSP30-EPS vaccineP-30-EPS vaccineP 30-EPS vaccineP30-linked EphA2, CMV pp65, and survivin peptide vaccine